SI 722 Seikagaku Corporation

View All

Interstitial-Cystitis-market-size-share-pipeline-analysis
Interstitial Cystitis: A big opportunities for emerging drugs

Interstitial Cystitis market comprises robust pipeline therapies in late and mid-stage development, which are expected to be launched shortly, such as KRP-116D (Kyorin Pharmaceutical), Certolizumab pegol/ Cimzia (UCB Pharma), LP-08 (Lipella Pharmaceuticals), GRT6010 (Grünenthal), ASP6294 (Astellas Pharma), and SI-...

Find More